November 11, 2022 – Daiichi Sankyo Wins EU Backing for Enhertu in Gastric Cancer

An expert panel of the European Medicines Agency (EMA) has recommended issuing marketing authorization for Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) to include gastric cancer as an indication for Enhertu, an antibody-drug conjugate the company develops with AstraZeneca (NASDAQ:AZN).

Read more>